Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

EMA approves OncoGenex's development plan for OGX-011

Feb. 26, 2010

Genta initiates once-weekly treatment schedule for tesetaxel

Feb. 26, 2010

Roche reports on phase III trial of Avastin in ovarian cancer

Feb. 26, 2010

Sigma-Tau reports identification of novel HSP90 inhibitors

Feb. 26, 2010

HSP90 inhibitor STA-9090 targets oncogenic functions of Wilms tumor protein in AML cells

Feb. 25, 2010

Enzon treats first pediatric cancer patient in phase I PEG-SN38 trial

Feb. 25, 2010

Phase III NOV-002 trial in NSCLC fails to meet primary endpoint

Feb. 25, 2010

Hutchison MediPharma presents novel epidermal growth factor receptor inhibitors

Feb. 25, 2010

Novel focal adhesion kinase inhibitors discovered at AstraZeneca

Feb. 25, 2010

European CHMP issues two positive opinions for GSK's Tyverb and Votrient in cancer

Feb. 24, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 6, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Latus Bio series A financing supports early-stage programs
BioWorld Science
Latus Bio Inc. has closed a $97 million series A financing to support its broad therapeutics pipeline based on novel AAV capsid variants. Proceeds from the...